Fails 3 of 8 criteria. S3, pharmacy identification: No pharmacy is named in the footer, the terms, the privacy policy, the safety page, the answers pages or the medication pages. The safety page says patients learn which pharmacy fills the prescription before it is filled. 2 more criteria also fail; see the table below.
At a glance
Options Medical Weight LossTelehealth service
5/8criteria passed
Price
Semaglutide from $199 a month on a 12-month plan paid in full, tirzepatide from $299
Sells
compounded semaglutide injections, compounded tirzepatide injections, and 10 more
Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.
A medical weight-loss clinic chain with clinics in four states and a telehealth program, selling compounded semaglutide and tirzepatide injections, oral GLP-1 options, phentermine, hormone therapy and NAD+ and glutathione injections after a free consultation. It names no pharmacy, and its home page calls its GLP-1 program FDA-approved.
Options Medical Weight Loss' GLP-1 product page; Options Medical Weight Loss' get your free consultation page; Options Medical Weight Loss' telehealth page
The evidence behind each disposition in the table above, where it appears, and its date.
S1PASSEvery prescription is written by a licensed, obesity-certified medical provider, and the telehealth program's provider reviews the patient's history in a video visit and decides whether GLP-1 medication is appropriate.Source: Options Medical Weight Loss' telehealth page; Options Medical Weight Loss' safety page.
S2PASSEvery Buy Now and Get Started button points to the free-consultation request page, and the telehealth page says care begins with a health questionnaire and a video visit in which the provider decides whether GLP-1 medication is right before anything is prescribed.Source: Options Medical Weight Loss' GLP-1 product page; Options Medical Weight Loss' get your free consultation page; Options Medical Weight Loss' telehealth page.
S3FAILNo pharmacy is named in the footer, the terms, the privacy policy, the safety page, the answers pages or the medication pages. The safety page says patients learn which pharmacy fills the prescription before it is filled.Source: Options Medical Weight Loss' safety page; Options Medical Weight Loss' terms and conditions; Options Medical Weight Loss' FAQ.
S4FAILThe home page presents its GLP-1 program as an FDA-approved GLP-1 weight-loss program, and that program's page says its GLP-1 injections are made in 503B outsourcing facilities with the same base formula as name-brand medications. The semaglutide medication page does state that compounded drug products are not approved or evaluated by the FDA.Source: Options Medical Weight Loss' website; Options Medical Weight Loss' GLP-1 premium page; Options Medical Weight Loss' GLP-1 product page.
S5FAILThe GLP-1 program page says its injections are tested for quality, sterility and consistency, and no certificate of analysis or lot document is published.Source: Options Medical Weight Loss' GLP-1 premium page; Options Medical Weight Loss' safety page.
S6PASS4301 4th St. North, Corp Suite #1, St. Petersburg, FL 33703, printed in the contact sections of the terms and the privacy policy.Source: Options Medical Weight Loss' terms and conditions; Options Medical Weight Loss' privacy policy.
S7PASSCompounded semaglutide injections at $199 a month on a 12-month plan paid in full, and from $199 a month on the telehealth pricing page. Compounded tirzepatide from $299 a month on the telehealth pricing page, while the home page prints tirzepatide from $399 a month. Oral semaglutide from $239 a month, oral tirzepatide from $339, phentermine from $149, and NAD+ and glutathione injections at $199 and $179 a month.Source: Options Medical Weight Loss' GLP-1 product page; Options Medical Weight Loss' telehealth page; Options Medical Weight Loss' website; Options Medical Weight Loss' NAD+ product page; Options Medical Weight Loss' glutathione product page.
S8PASSNo FDA warning letter names Options Medical Weight Loss, and no action has halted the business.Source: FDA warning-letter index.
Products shown on the seller's own pages at the recorded date: compounded semaglutide injections, compounded tirzepatide injections, oral semaglutide, oral tirzepatide, phentermine, NAD+ injections, glutathione injections, B12 injections, lipotropic injections, testosterone, estrogen, progesterone.
Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.